Myeloma Canada invests a yearly record-high $735,000 in Canadian myeloma research projects
Myeloma Canada invested in more important research initiatives in 2020 than in any other year, thanks to...
Read moreResearch & Access Updates
Inaugural Coverage of the 62nd ASH Annual Meeting & Exposition by the CMRG.
Take a look at this all-virtual 4-day event recap, with a 90-minute panel discussion on the CMRG YouTube...
Read moreCanadian perspective on managing multiple myeloma during the COVID-19 pandemic: lessons learned and future considerations
The coronavirus disease 2019 (covid-19) pandemic caused by the novel severe acute respiratory syndrome co...
Read moreNirogacestat in Combination with PF‐06863135 in Patients with Relapsed or Refractory Multiple Myeloma
SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on deve...
Read moreTriplet Regimens Dominate the Relapsed/Refectory Myeloma Treatment Landscape
Novel triplet combinations are leading the key developments made in the treatment of patients with relaps...
Read moreJanssen files Darzalex Faspro for rare disease light chain amyloidosis
Janssen has filed a new formulation of its Darzalex in the US for the rare and potentially fatal disease...
Read more